The record → All 128 providers → Hims
Provider Dossier · hims.com · Last verified 3 November 2026
Is Hims legit?
Quick answerLast verified · GLP-1 Dossier Editorial Desk
Our enforcement sweep matched 4 primary-sourced regulatory or legal actions on file involving Hims (hims.com), each linked to the original document below.
Published prices start at $149/mo; that figure is a membership or consultation fee, with medication billed separately.
It now lists FDA-approved medication only, after ending compounded GLP-1 sales.
Disclosure: Unmonetized direct link (Hims has no commercial relationship with this site).
Yes. Hims (hims.com) is a legitimate, operating US telehealth company, though its GLP-1 offering has changed substantially after federal litigation. Following legal action recorded below, Hims transitioned away from marketing compounded GLP-1 formulations and now lists FDA-approved medication only.
Our regulatory file holds 4 primary-sourced actions involving Hims (linked directly to the court docket and FDA records below). Check current sign-up availability and whether your prescription is fulfilled as a cash-pay branded drug or through insurance before enrolling.
Comparing Hims against fda-approved medication only providers with 0 actions on file
Hims has 4 regulatory or legal actions documented below. For readers comparing transparent options in the same supply category before entering payment details, these providers have 0 actions on file and published monthly pricing:
- Website & Terms inspected
- hims.com (Direct checkout & Terms of Service verified)
- Last price & terms read
- 16 November 2026 (Separate membership fee + medication billed on top)
- 503A / 503B pharmacy disclosure
- FDA-approved retail or manufacturer-direct pharmacy fulfillment
- Public registries searched
- FDA CDER Warning Letters (2024–2026), Federal District Court Dockets (PACER / CourtListener), FTC Enforcement Actions, NAD Case Reports → 4 primary document linked belows
- Researcher field note
- Hims was the flagship compounded-semaglutide seller but is branded-only as of the 9 March 2026 Novo Nordisk settlement; third-party content describing Hims as a compounder is out of date. Medication prices run $149/mo (Wegovy Pill) to $1,899/mo (Mounjaro, Zepbound) on top of the membership.
What it actually supplies
Supplies FDA-approved medication only (Wegovy, Zepbound, Ozempic, Mounjaro, or the approved oral versions). Higher priced, and outside compounding enforcement entirely.
Named on its own site (hims.com): Wegovy Pill, Wegovy Pen, Zepbound Vial, Zepbound KwikPen, Ozempic, Ozempic Pill, Mounjaro, Foundayo (orforglipron).
What regulators and courts have said
Every entry below links to its original document and identifies the source type. We publish what the official record states and nothing beyond it; a regulatory letter or lawsuit involving a company is not proof that an individual patient was harmed.
September 2025
FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing.
March 2026
Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide.
July 2026
The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven.
June 2025
Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.
Other signals on file
Not regulatory or legal actions, and never counted as such. We log these items separately because they are sourced and relevant to prospective patients (complaint volumes, corporate and pharmacy disclosures, third-party lab reports, or commercial disputes).
June 2025
Novo Nordisk terminated its collaboration with Hims & Hers, alleging illegal sham compounding and Chinese-sourced unapproved API.
Corporate entity, pricing & cancellation terms
Hims was the flagship compounded-semaglutide seller but is branded-only as of the 9 March 2026 Novo Nordisk settlement; third-party content describing Hims as a compounder is out of date. Medication prices run $149/mo (Wegovy Pill) to $1,899/mo (Mounjaro, Zepbound) on top of the membership.
Go direct
The button below is a plain direct link to Hims and earns us nothing. Hims has no commercial arrangement with this desk and is documented under the exact same verification rules as companies that do pay.
Visit Hims (hims.com) →Lower advertised starting prices
Providers advertising a lower monthly entry figure. Check each dossier before comparing two numbers: the headline price alone does not tell you whether medication is included.
Side-by-side records
Compared with the alternatives
Direct dossier comparisons for the providers patients most frequently weigh against Hims.
Long-form provider files
Full price tables, terms and records
Every plan length, the refund and cancellation terms, named pharmacies, review-site links and each regulatory action with its primary document. These 6 providers pay us a referral commission if you sign up through our links; ordered by lowest verified monthly price only.
| Provider file | Sema. /mo | Tirz. /mo | Actions on file | Links |
|---|---|---|---|---|
| Embody | $49 | $99 | None | Read the dossier →Embody site ↗ |
| Belle | $93 | $149 | 1 | Read the dossier →Belle site ↗ |
| PlexusDx | $99 | $129 | None | Read the dossier →PlexusDx site ↗ |
| MEDGm | $169 | $269 | None | Read the dossier →MEDGm site ↗ |
| DirectMeds | $249 | $399 | 1 | Read the dossier →DirectMeds site ↗ |
| GoodLife Health | $299 membership | + brand-name drug | None | Read the dossier →GoodLife Health site ↗ |
- Embodyfrom $49/moSema. $49 · Tirz. $99None on file
- Bellefrom $93/moSema. $93 · Tirz. $1491 on file
- PlexusDxfrom $99/moSema. $99 · Tirz. $129None on file
- MEDGmfrom $169/moSema. $169 · Tirz. $269None on file
- DirectMedsfrom $249/moSema. $249 · Tirz. $3991 on file
- GoodLife Healthfrom $299/mo + drugMembership; brand-name drug billed separatelyNone on file
Each row has two links: “Read the dossier” opens our file on that provider, and the “site ↗” button opens the provider’s own site in a new tab. Nothing else in the row is a link. Where a provider runs an affiliate programme with us, its site button is a referral link and we may earn a commission at no cost to you. It never changes the order or what is on file.
Reference notes
Hims: key questions answered
- Is Hims (hims.com) legit or a scam? What does the public record show?
- Yes. Hims (hims.com) is an active, operating US weight-loss telehealth company. Following federal litigation, it transitioned away from compounded GLP-1 marketing and now prescribes FDA-approved medications only. Our regulatory sweep matched 4 primary-sourced regulatory or legal actions on file: FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing; Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide; The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven; Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven.
- Does Hims sell compounded or FDA-approved weight loss medication?
- FDA-approved medication only. Supplies FDA-approved medication only (Wegovy, Zepbound, Ozempic, Mounjaro, or the approved oral versions). Higher priced, and outside compounding enforcement entirely. Specifically named on hims.com: Wegovy Pill, Wegovy Pen, Zepbound Vial, Zepbound KwikPen, Ozempic, Ozempic Pill, Mounjaro, Foundayo (orforglipron).
- What are Hims weight loss pricing, hidden fees, and cancellation terms?
- Hims (hims.com) publishes weight-loss plans starting at $149 per month, with the medication itself billed separately at the pharmacy, alongside a promotional or bundle rate of $39. Contract and billing terms: $39 first month then $149/month, auto-renewing; medication billed separately. Hims was the flagship compounded-semaglutide seller but is branded-only as of the 9 March 2026 Novo Nordisk settlement; third-party content describing Hims as a compounder is out of date. Medication prices run $149/mo (Wegovy Pill) to $1,899/mo (Mounjaro, Zepbound) on top of the membership.
- What compounding or fulfillment pharmacy does Hims use?
- Hims (hims.com) prescribes FDA-approved medications only (such as Wegovy, Zepbound, Ozempic, or Mounjaro), which are manufactured by Novo Nordisk or Eli Lilly in FDA-inspected facilities and dispensed through retail, mail-order, or manufacturer-direct pharmacies rather than compounded by a 503A/503B compounding pharmacy.
- Are there FDA warning letters, lawsuits, or regulatory complaints against Hims?
- Yes. We hold 4 primary-sourced regulatory or legal actions on record involving Hims (hims.com): FDA warning letter to Hims & Hers Health, Inc. dba Hims (MARCS-CMS 716567) over compounded GLP-1 marketing; Novo Nordisk sued Hims & Hers for infringement of US Patent 8,129,343 in the District of Delaware on 9 February 2026 (No. 1:26-cv-00143) and voluntarily dismissed it without prejudice on 9 March 2026, expressly reserving the right to refile, under an agreement in which Hims & Hers stopped advertising compounded GLP-1s and began distributing Novo's FDA-approved semaglutide; The FTC, the State of Utah and Los Angeles County sued Hims & Hers Health, Inc. in the Northern District of California under FTC Act section 5 and ROSCA, alleging the company disclosed customers' health information to advertising platforms including Meta and Snap, charged consumers before the promised provider consultation, and obstructed cancellation; allegations unproven; Consolidated securities class action, In re Hims & Hers Health, Inc. Securities Litigation, No. 25-cv-05315 (N.D. Cal.), first filed 25 June 2025, alleging misrepresentations about the company's business and its Novo Nordisk relationship; disclosed by the company in its Form 10-Q for the quarter ended 30 June 2026. Allegations unproven. Every entry links directly to the primary FDA, NAD, or court document on this page. Separately from regulatory enforcement, our file notes 1 other sourced signal: Novo Nordisk terminated its collaboration with Hims & Hers, alleging illegal sham compounding and Chinese-sourced unapproved API.
- How do Hims oral GLP-1 tablets or sublingual drops compare with FDA-approved oral semaglutide?
- Hims (hims.com) prescribes FDA-approved oral GLP-1 medication (Wegovy Pill, Wegovy Pen, Zepbound Vial, Zepbound KwikPen, Ozempic, Ozempic Pill, Mounjaro, Foundayo (orforglipron)), such as Novo Nordisk's oral semaglutide (Rybelsus or Wegovy pill) or other FDA-approved oral weight-loss medications, dispensed in manufacturer-sealed packaging rather than compounded sublingual tablets or drops.